Clinical research laboratory ApoCell believes it may have hit on a viable alternative to current tools for finding circulating tumor cells, and its funders at the National Cancer Institute’s Small Business Innovation Research division seem to agree.
The firm's ApoStream technology, licensed from the M.D. Anderson Cancer Center in Houston, separates circulating tumor cells (CTCs) from healthy blood cells using a low-level electrical field of varying frequencies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?